The SUM-159PT cell line was derived from the primary tumor of a patient with a breast neoplasm. The tumor was originally classified as either an anaplastic carcinoma or a sarcoma as it was highly undifferentiated. True to that diagnosis, the cells that we cultured looked like transformed fibroblasts when cultured in serum-containing medium, but they transformed to epithelial morphology in serum-free medium. MYC and HRAS are the driving oncogenes for this cell line. There is a high level and highly focal MYC amplification, and a classical HRAS mutation. These cells were later determined to be a basal breast cancer cell line of the claudin-low subtype and the cells exhibit many characteristics of breast cancer stem cells.
Okay, let’s delve more deeply into the SUM-159 cell line.
- Characteristics of the patient from which SUM-159 was derived
- The oncogenes of the SUM-159 cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- The functional-druggable signature for SUM-159 cells
- Differential drug sensitivity data from Heiser et al.
- Bibliography of published papers in which SUM-159 cells were used
- SUM-159 blog
Back to the SUM Cell Line Gateway
